Literature DB >> 20001495

Short time infusion of bevacizumab in combination with 5FU-based chemotherapy as first-line therapy in a non-selective patient group with metastatic colorectal cancer.

Line H Dohn, Benny V Jensen, Finn O Larsen.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20001495     DOI: 10.3109/02841860903428184

Source DB:  PubMed          Journal:  Acta Oncol        ISSN: 0284-186X            Impact factor:   4.089


× No keyword cloud information.
  3 in total

1.  Safety of bevacizumab 7.5 mg/kg infusion over 10 minutes in NSCLC patients.

Authors:  Olivier Mir; Jérôme Alexandre; Romain Coriat; Stanislas Ropert; Pascaline Boudou-Rouquette; Thach Bui; Jeanne Chapron; Jean-Philippe Durand; Daniel Dusser; François Goldwasser
Journal:  Invest New Drugs       Date:  2011-05-26       Impact factor: 3.850

2.  Thirty-minutes infusion rate is safe enough for bevacizumab; no need for initial prolong infusion.

Authors:  Mustafa Teoman Yanmaz; Sebnem Izmır Guner; Bahar Satılmıs; Huseyın Akyol; Mehmet Akıf Aydın
Journal:  Med Oncol       Date:  2014-10-08       Impact factor: 3.064

3.  Safety of bevacizumab in treating metastatic colorectal cancer: a systematic review and meta-analysis of all randomized clinical trials.

Authors:  Fei Dai; Lixing Shu; Yangfang Bian; Zhuo Wang; Zhangwei Yang; Wengong Chu; Shen Gao
Journal:  Clin Drug Investig       Date:  2013-11       Impact factor: 2.859

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.